Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.64 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.64 |
| ▸ | GAPDH | P04406 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | STAT6 | P42226 | 1/20 | 0.64 |
| ▸ | PI4KA | P42356 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.64 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.64 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.64 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10345916 | 0.90 | ADORA1 (0.61) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8651426 | 0.82 | ADORA1 (0.64) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL10586178 | 0.82 | ADORA1 (0.64) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL11875120 | 0.82 | AHCY (0.70) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL1553824 | 0.82 | ADORA1 (0.64) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL7803298 | 0.82 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL2040670 | 0.82 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL5024895 | 0.82 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL12963362 | 0.82 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL10997946 | 0.82 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020169140-A1 | Combination therapy for reduction of toxicity of chemotherapeutic agents | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | claimed |
| WO-2002069949-A2 | COMBINATION THERAPY FOR REDUCTION OF TOXYCITY OF CHEMOTHERAPEUTIC AGENTS | PRENDERGAST PATRICK T (IE) | 2002-09-12 | — | — | WO | claimed |
| US-20180311237-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | ZPNE GROUP GMBH (CH) | 2018-11-01 | — | — | US | disclosed |
| US-20150031701-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | ZPNE GROUP GMBH (CH) | 2015-01-29 | — | — | US | disclosed |
| US-20130259930-A1 | Compositions and Methods for Preventing and Treating Mucositis and Weight Loss | CASCADE ESTATE LTD. (MU) | 2013-10-03 | — | — | US | disclosed |
| US-20100092547-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | ZPNE GROUP GMBH (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2134347-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | Prendergast, Patrick T. (AU) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008110585-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | PRENDERGAST PATRICK T (AU) | 2008-09-18 | — | — | WO | disclosed |
| US-20080139496-A1 | COMBINATION THERAPY FOR REDUCTION OF TOXICITY OF CHEMOTHERAPEUTIC AGENTS | CASCADE ESTATE LTD. (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20020169140-A1 | Combination therapy for reduction of toxicity of chemotherapeutic agents | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002069949-A2 | COMBINATION THERAPY FOR REDUCTION OF TOXYCITY OF CHEMOTHERAPEUTIC AGENTS | PRENDERGAST PATRICK T (IE) | 2002-09-12 | — | — | WO | disclosed |
| WO-1998047516-A1 | COMBINATION THERAPY UTILISING 17-KETOSTEROIDS AND INTERLEUKIN INHIBITORS, OR INTERLEUKIN-10 POTIONALLY WITH INTERLEUKIN INHIBITORS | PRENDERGAST PATRICK T (IE) | 1998-10-29 | — | — | WO | disclosed |
| EP-0462621-A2 | Use of particular compounds for manufacture of pharmaceutical formulations for treatment against various parasites, mycoplasmas, other indications and other infections | Prendergast, Patrick Thomas (IE) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311237-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | SI, MTPN, MUC1 | ADORA1 2214/4885SMN1; SMN2 254/4885ADORA3 3145/4885 |
| US-20100092547-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | MTAP, TPMT, MUC1 | ADORA1 32/4885SMN1; SMN2 4149/4885ADORA3 56/4885 |
| US-20150031701-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS | SI, MTPN, MUC1 | ADORA1 2214/4885SMN1; SMN2 254/4885ADORA3 3145/4885 |
| US-20130259930-A1 | Compositions and Methods for Preventing and Treating Mucositis and Weight Loss | SI, MTPN, MUC1 | ADORA1 2214/4885SMN1; SMN2 254/4885ADORA3 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.